The New York Proton Center has initiated three FLASH radiation therapy mouse model studies that will examine the use of FLASH RT to improve treatment of lung, pelvic, and abdominal tumors. NYPC researchers are conducting the studies in partnership with oncologists at Memorial Sloan Kettering Cancer Center, Montefiore Einstein Cancer Center, and Mount Sinai Health System.
Researchers at MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer, highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors. The study was published in Cancer Cell.
A study by New York University researchers, published this week in the journal Proceedings of the National Academy of Sciences, explains why cancers not only stop responding to kinase inhibitors but come back stronger, a finding that could inform which drugs oncologists use as a first-line treatment.
The phase III NRG-GY018 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival for the treatment of patients with stage 3-4 or recurrent endometrial carcinoma regardless of mismatch repair status.
In an article published in Nature Medicine, Moffitt Cancer Center researchers, led by Hatem Soliman, share results from a phase II clinical study of the oncolytic virus talimogene laherparepvec combined with standard chemotherapy in patients with early stage triple-negative breast cancer.
Awareness of breast density appears to increase one’s perceived breast cancer risk for a short time after undergoing mammography in Northern Manhattan according to a study at Columbia University Mailman School of Public Health.
A team of researchers at Wistar’s Ellen and Ronald Caplan Cancer Center has identified a gene signature that accurately predicts the functioning of P53 variants—important for assessing cancer risk and optimizing choices for cancer therapeutics.
New research led by investigators at Massachusetts General Hospital shows that the blood pressure drug losartan can prevent immunotherapy-induced edema in patients with glioblastoma.
Researchers with The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute are investigating how dietary interventions could help reduce fatigue, improve diet quality and help cancer patients live an overall better quality of life.
Research from UPMC Hillman Cancer Center is challenging the prevailing hypothesis for how donor stem cell grafts cause graft-versus-host disease and offers an alternative model that could guide development of novel therapies.
